The results of a research collaboration between the neuroscience group of…
Category: Therapeutic Areas
Ever wish that really big hill you always cycle up would…
Cannabinoid bioscience has come a long way. New York-based Axim Biotech…
Read the original Exelexis-supported publication in Drug Metabolism & Disposition (DMD)….
Introduction Researchers are developing novel, safer treatments for cancer, but bringing new oncology therapies to market is challenging. This white paper will examine the…
Introduction As global obesity rates continue to rise, the search for effective treatments is more critical than ever. Obesity is associated with an increased…
Introduction Changes in how clinical trials are managed in the European Union (EU), mandated by the European Union Clinical Trial Regulation 536/2014 (EU CTR),…
NEWARK, Delaware, November 13, 2024/BUSINESS WIRE/ — QPS Holdings, LLC announced today that their Springfield campus, QPS Missouri, has launched a new Cell Therapy…
NEWARK, Delaware, June 26, 2024/BUSINESS WIRE/ — QPS Holdings, LLC (QPS), a leading global contract research organization (CRO), is pleased to announce new laboratory…
NEWARK, Delaware, June 10, 2024/BUSINESS WIRE/ — QPS Holdings, LLC (QPS), a leading global contract research organization (CRO), is pleased to announce new clinical…
QPS has a Strong Competency in Alzheimer Research
May 9, 2019
The results of a research collaboration between the neuroscience group of QPS Netherlands B.V. and Professor Peter Paul de Deyn and coworkers of the Department
Writing the Book on Beta-Alanine for Sports Performance: QPS MRA’s Doug Kalman Takes a Stand
August 11, 2015
Ever wish that really big hill you always cycle up would seem a little less hilly? Want to swing impressive poundage at your next kettlebell
QPS Aids Development of Cannabinoid Chewing Gum, for MS Patients
August 11, 2015
Cannabinoid bioscience has come a long way. New York-based Axim Biotech is at the forefront, developing – among many other, related products – a multi-layered,
DMPK scientists from Exelixis and QPS publish on “Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites” in DMD
July 27, 2015
Read the original Exelexis-supported publication in Drug Metabolism & Disposition (DMD). Cabozantinib (COMETRIQ®) inhibits the activity of tyrosine kinases including MET, VEGFRs and RET. These
Introduction Researchers are developing novel, safer treatments for cancer, but bringing new oncology therapies to market is challenging. This white paper will examine the…
Introduction As global obesity rates continue to rise, the search for effective treatments is more critical than ever. Obesity is associated with an increased…
Introduction Changes in how clinical trials are managed in the European Union (EU), mandated by the European Union Clinical Trial Regulation 536/2014 (EU CTR),…
NEWARK, Delaware, November 13, 2024/BUSINESS WIRE/ — QPS Holdings, LLC announced today that their Springfield campus, QPS Missouri, has launched a new Cell Therapy…
NEWARK, Delaware, June 26, 2024/BUSINESS WIRE/ — QPS Holdings, LLC (QPS), a leading global contract research organization (CRO), is pleased to announce new laboratory…
NEWARK, Delaware, June 10, 2024/BUSINESS WIRE/ — QPS Holdings, LLC (QPS), a leading global contract research organization (CRO), is pleased to announce new clinical…
